Ribera Juan, Payo-Ollero Jesús, Serrano-Toledano David, Del Río-Arteaga Marta, Montilla Francisco Javier, Muela Rafael
Clínica COT. C/ Juan Ramón, Jiménez 29, 41011, Seville, Spain.
Hospital Viamed Santa Ángela de La Cruz. Orthopaedic Surgery and Traumatology Department. Av. de Jerez, 59, 41014, Seville, Spain.
Eur J Orthop Surg Traumatol. 2024 Feb;34(2):1183-1192. doi: 10.1007/s00590-023-03783-9. Epub 2023 Nov 25.
To determine the survival and patient-reported outcomes in non-oncological patients treated with proximal femoral resection (PFR) using MEG for femoral reconstruction.
This retrospective study included 16 patients. Demographic variables and complications developed were analyzed. Clinical-functional outcomes were measured using the modified Harris score (mHSS), numeric Pain Rating Scale (NPRS) and Musculoskeletal Tumor Society (MSTS) score. MEG survival was estimated using a Kaplan-Meier survival analysis.
Average follow-up was 5 years (range, 1-9). The 75% of patients were overweight and women with an average age of 74.2 ± 5.9-years (BMI of 28.5 ± 4.2 kg/m). The main cause of MEG was periprosthetic infection (43.7%). The 50% of patients had post-surgical complications regarding with MEG, being the most frequent seromas and MEG dislocation. Implant survival was 93.4% and 80.9% at 3 and 7 years of follow-up, respectively. The functional results at the end of the follow-up with respect to the pre-surgical state improved from 9.5 ± 2.6 to 3 ± 0.9 mean NPRS and 26.5 ± 6.8 to 69.5 ± 13.5 mean mHHS, p < 0.001, respectively. The mean MSTS score was 68.1% that these results were considered excellent.
The MEG for reconstruct III-IV femoral defects is a good therapeutic option that offers an acceptable clinical-functional result. Short-term and medium-term survival was greater than 80%. The most frequent complications are seromas and MEG dislocation. The use of constrained liner and abductor system reconstruction is essential to prevent the dislocation.
确定采用金属增强型植入物(MEG)进行股骨近端切除(PFR)治疗非肿瘤患者后的生存率及患者报告的结局。
这项回顾性研究纳入了16例患者。分析了人口统计学变量及出现的并发症。使用改良Harris评分(mHSS)、数字疼痛评分量表(NPRS)和肌肉骨骼肿瘤学会(MSTS)评分来衡量临床功能结局。采用Kaplan-Meier生存分析评估MEG的生存率。
平均随访时间为5年(范围1 - 9年)。75%的患者超重,为女性,平均年龄74.2±5.9岁(体重指数为28.5±4.2kg/m²)。MEG的主要原因是假体周围感染(43.7%)。50%的患者在MEG术后出现并发症,最常见的是血清肿和MEG脱位。随访3年和7年时,植入物生存率分别为93.4%和80.9%。随访结束时相对于术前状态的功能结果,平均NPRS从9.5±2.6改善至3±0.9,平均mHHS从26.5±6.8改善至69.5±13.5,p均<0.001。平均MSTS评分为68.1%,这些结果被认为是优秀的。
MEG用于重建III - IV级股骨缺损是一种良好的治疗选择,可提供可接受的临床功能结果。短期和中期生存率大于80%。最常见的并发症是血清肿和MEG脱位。使用限制性衬垫和外展肌系统重建对于预防脱位至关重要。